Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Sponsor: Emory University
Listed as NCT04890236, this EARLY_PHASE1 trial focuses on Recurrent Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma and remains completed. Sponsored by Emory University, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Completed EARLY_PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2022 — Nov 2023 [monthly]
Recruiting EARLY_PHASE1
▶ Show 4 earlier versions
-
Apr 2022 — Jul 2022 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Apr 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- National Cancer Institute (NCI)
- Novartis
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .